Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 6:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–68 of 68 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Atorvastatin 10 mg Clear all
Recruiting Phase 4 Interventional

AtorvaStatin Postpartum and Reduction of Cardiovascular risK

NCT06632379
View directory record Official record
Conditions
Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
Interventions
Atorvastatin 10 mg, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants

NCT04608344
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Atorvastatin, Pravastatin, Rosuvastatin, Filgotinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 4 Interventional Results available

Statin Therapy for Ischemic and Nonischemic Cardiomyopathy

NCT00701220
View directory record Official record
Conditions
Cardiovascular Disease, Cardiomyopathy, Heart Disease, Myocardial Disease, Myocardial Ischemia
Interventions
Atorvastatin Calcium
Drug
Lead sponsor
Philip Binkley
Other
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 4 Interventional Results available

Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication

NCT00715273
View directory record Official record
Conditions
Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
Interventions
Atorvastatin, Niacin, Colesevelam, Placebo Niacin, Placebo Colesevelam
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 70 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Boise, Idaho • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

NCT01709513
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin, Ezetimibe, Alirocumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
41
States / cities
Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet

NCT00917579
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling

NCT02437084
View directory record Official record
Conditions
Hyperlipidemia, Insulin Resistance, Type 2 Diabetes
Interventions
Atorvastatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Statins in Children With Type 1 Diabetes and Hypercholesterolemia

NCT01236365
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent, Hypercholesterolemia
Interventions
Atorvastatin, Atorvastatin Placebo
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
10 Years to 20 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
5
States / cities
Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

NCT00359281
View directory record Official record
Conditions
Healthy
Interventions
atorvastatin, simvastatin, ezetimibe, fenofibrate, dextromethorphan, Extended Release Niacin
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

The SCCS Polypill Pilot Trial

NCT02278471
View directory record Official record
Conditions
Hypertension, Hyperlipidemia
Interventions
Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
45 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

NCT03051100
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Bempedoic acid 180mg, Ezetimibe 10mg, Atorvastatin 20mg, Placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
11
States / cities
Champaign, Illinois • Cary, North Carolina • Charlotte, North Carolina + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)

NCT03311841
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Midazolam oral solution, Dabigatran and pitavastatin oral solution, Atorvastatin and rosuvastatin oral solution, Rifampin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 78 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study

NCT00728910
View directory record Official record
Conditions
Dyslipidemia
Interventions
Atorvastatin, ABT335, ER Niacin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia

NCT00474240
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin 20 mg, AEGR-733 5 mg, AEGR-733 10 mg, Placebo, AEGR-733 5 mg + atorvastatin 20 mg, AEGR-733 10 mg + atorvastatin 20 mg
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Huntsville, Alabama • Jacksonville, Florida • Ocala, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.

NCT01138072
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2248761, Simvastatin, Atorvastatin, Rosuvastatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2010 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

NCT02714569
View directory record Official record
Conditions
Dyslipidemias
Interventions
LY3202328, Placebo, Atorvastatin, Simvastatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
4
States / cities
Miami, Florida • Lenexa, Kansas • Marlton, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 4 Interventional

SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia

NCT00194402
View directory record Official record
Conditions
Dyslipidemia
Interventions
Slo-Niacin, atorvastatin
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 6, 2026, 6:59 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Evaluation of Atorvastatin Treatment on Carotid Plaque.

NCT00343655
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Atorvastatin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 6, 2026, 6:59 PM EDT
Terminated Phase 4 Interventional Results available

Quality of Life in Patients With Statin-Associated Myopathy

NCT00850460
View directory record Official record
Conditions
Statin Adverse Reaction
Interventions
Statins, Placebo
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
40 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 6, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients

NCT03611010
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemias
Interventions
Atorvastatin injection
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 6, 2026, 6:59 PM EDT